I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Leave site
Roche and Genentech at

AAN 2025

We will be contributing to topics related to
-
08:36 PM
Duration 12mins San Diego Convention Center | 30C-E
Imaging and Fluid Biomarkers of Disability Progression During Two Years of Ocrelizumab Treatment in Black/African American and Hispanic/Latino People With Multiple Sclerosis (MS) in CHIMES
Amezcua, Lilyana; Monson, Nancy L.; Williams, Mitzi J.; Reder, Anthony T.; Wu, Gregory F.; Vartanian, Timothy; Pei, Jinglan; Harp, Christopher; Clayton, David; Abioye, Ibraheem; Bernitsas, Evanthia
04:15 PM
Duration 10mins Ballroom 20
Placental and Breastmilk Transfer of Ocrelizumab from Women with Multiple Sclerosis to Infants and the Potential Impact on B-Cell Levels: Primary Analysis of the Prospective, Multicenter, Open-Label, Phase IV Studies MINORE and SOPRANINO
Bove, Riley; Oreja-Guevara, Celia; Vukusic, Sandra; Shah, Anna; Graham, Edith L.; McElrath, Thomas; Pietrasanta, Carlo; Dobson, Ruth; Maillart, Elisabeth; Jacobs, Dina; Kletzl, Heidemarie; Kazlauskaite, Agne; Zecevic, Dusanka; Raposo, Catarina; Craveiro, Licinio; Lin, Chien-Ju; Pasquarelli, Noemi; Hellwig, Kerstin
06:45 PM
Duration 60mins California, USA
Reduced cerebrospinal fluid biomarkers (neurofilament light chain, B cells, T cells) and improved clinical/imaging assessments of disease activity are sustained after 5 years of ocrelizumab treatment: long-term extension results from OBOE
Gelfand, Jeffrey; Bar-Or, Amit; Agbim, Chinaza; von Büdingen, H. Christian; Cameron, Briana; Casavant, Ellen; Herman, Ann E.; Jia, Xiaoming; Ramesh, Akshaya; Winger, Ryan; Jiang, Jenny; Harp, Chris; Cross, Anne
03:00 PM
Duration 60mins California, USA
Ocrelizumab Subcutaneous Administration: Further Characterization of the Benefit-Risk Profile From the OCARINA II Study and Patient Preferences
Newsome, Scott D; Goldstick, Lawrence; Selmaj, Krzysztof; Krzystanek, Ewa; Zecevic, Dusanka; Figueiredo, Catarina; Clinch, Susanne; Giacobino, Caroline; Azmi, Jay; Centonze, Diego
Duration 60hrs California, USA
Fenebrutinib maintains low disease activity in relapsing multiple sclerosis: results from the FENopta trial open-label extension
Bar-Or, Amit; Oh, Jiwon; Dufek, Michal; Budincevic, Hrvoje; Habek, Mario; Caunt, Maresa; Sierzega, Malgorzata; Clayton, David; Chen, Ying-Fang; Ratchford, John N.; Goodyear, Alexandra; Drulovic, Jelena
10:54 PM
Duration 12mins San Diego Convention Center | 29CD
Evaluation of CHIT1 and SERPINA3 as Candidate Cerebrospinal Fluid Biomarkers of Progressive Biology in Multiple Sclerosis
Bar-Or, Amit; Gelfand, Jeffrey; Agbim, Chinaza; von Büdingen, H. Christian; Cameron, Briana; Casavant, Ellen; Herman, Ann E.; Jia, Xiaoming; Ramesh, Akshaya; Winger, Ryan; Jiang, Jenny; Harp, Chris; Cross, Anne
Coming soon